Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of CMS121 and Lemairamin — mechanism, side effects, legal status, and pricing.
CMS121 is a non-peptide small-molecule quinoline, a synthetic analog of the natural flavonoid fisetin, developed to inhibit fatty acid synthase (FASN) and reduce lipid peroxidation in neuronal cells. It has completed a Phase 1 safety and pharmacokinetics trial in healthy volunteers (NCT05318040) but has no approved medical use and no published human efficacy data in Alzheimer's disease or any other condition. The compound is sold by research-chemical suppliers for laboratory use only; some direct-to-consumer vendors incorrectly market it as a "peptide" supplement despite its small-molecule structure.
Lemairamin is a non-peptide small-molecule cinnamamide alkaloid (N-phenethyl cinnamide) natural product, not approved for human use in any jurisdiction. All available data are preclinical (rodent, zebrafish, C. elegans, in vitro, and computational). It is sold exclusively as an unregulated 'research chemical' explicitly labeled 'not for human consumption'; quality, purity, and identity are not independently verified by any regulatory body. No human clinical trials, pharmacokinetic studies, or safety data exist.
CMS121
Lemairamin
Category
Legal Status
Mechanism
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
CMS121
Lemairamin
No pricing data yet.
Check Lemairamin prices →COA corpus from Disclosed Labs — independently tested batches only.
CMS121
3
COAs
99.1%
Avg purity
2
Labs
Lemairamin
2
COAs
99.8%
Avg purity
2
Labs
In APPswe/PS1dE9 double-transgenic mice (a model of Alzheimer's disease), dietary CMS121 (~34 mg/kg/day for 3 months starting at 9 months of age) normalized elevated hippocampal 4-HNE lipid-peroxidation adducts to wild-type levels, reduced 15-LOX2 and GFAP expression, and reversed cognitive deficits in Morris water maze testing to performance indistinguishable from wild-type mice. In vitro, CMS121 reduced iNOS, COX2, and TNF-α induction and blunted lipid-peroxidation increases in LPS-activated microglial cell cultures. A completed Phase 1 trial in approximately 100 healthy volunteers (NCT05318040) tested single oral doses up to 1800 mg and repeat doses up to 900 mg/day in young adults (600 mg/day in elderly subjects) for 7 days, reporting generally well-tolerated safety profiles with the majority of adverse events classified as mild; no serious adverse events were reported. Elderly subjects showed higher systemic exposure and longer terminal half-life than young adults, and fed-state exposure was approximately 50% higher than fasted with delayed absorption. No human efficacy data exist in Alzheimer's disease patients or any patient population.
Key references
No human data exist. No completed or registered human clinical trials were located on ClinicalTrials.gov, and no PubMed-indexed human pharmacokinetic, safety, or efficacy studies exist. All available data are preclinical: In transgenic Alzheimer's mice, gx-50 disassembled Aβ oligomers, decreased cortical Aβ accumulation, inhibited Aβ-induced neuronal apoptosis and calcium toxicity, improved Morris water maze performance, and was reported to cross the blood-brain barrier (Tang et al. 2013). In mouse and rat pain models (formalin tonic, neuropathic, bone-cancer pain), subcutaneous and intrathecal lemairamin dose-dependently reduced pain hypersensitivity/mechanical allodynia without evident tolerance, linked to spinal α7 nAChR activation and downstream IL-10/β-endorphin release (Wang et al. 2020). Murine microglial cell cultures showed gx-50 activation of α7 nAChR engaged JAK2/STAT3 and PI3K/AKT signaling to suppress pro-inflammatory cytokine secretion (Shi et al. 2016). Zebrafish DSS-induced colitis models showed lemairamin attenuated intestinal inflammation via Akt signaling (2024). C. elegans studies reported WGX-50 promoted markers of healthy ageing (daf-16/skn-1 longevity genes, 2025).
CMS121 and Lemairamin are both in the Cognitive category and may have overlapping mechanisms. Researchers should review both profiles carefully, understand the mechanisms of action, and monitor the relevant biomarkers when combining compounds in the same class. As always, consult a licensed healthcare provider before making any decisions about combining research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Key references
Disclosed Labs